Bio­gen down­plays ca­pac­i­ty for M&A; Roche’s SMA drug is ap­proved as a tablet

Plus, news about Odyssey Ther­a­peu­tics, GSK, Ali­gos Ther­a­peu­tics, Ter­rain Bio­sciences, the Gates Foun­da­tion and Ne­upho­ria Ther­a­peu­tics:

Bio­gen ap­pears to back away from deal­mak­ing pro­jec­tions: The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER